68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions

Breast CarcinomaEstrogen Receptor Positive

Interventions

DRUG

Gallium Ga 68-labeled GRPR Antagonist BAY86-7548

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

DEVICE

Investigational software and coils in PET/MR scan

General Electric (GE) Healthcare non-approved PET scanner coils and software

Trial Locations (1)

Stanford Cancer Institute Palo Alto, Palo Alto

All Listed Sponsors

collaborator

General Electric

INDUSTRY

lead

Andrei Iagaru

OTHER

NCT03831711 - 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | Biotech Hunter | Biotech Hunter